Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors
Crossref DOI link: https://doi.org/10.1186/s12885-016-3016-4
Published Online: 2017-01-05
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Zhang, Hai-Liang
Sheng, Xi-Nan
Li, Xue-Song
Wang, Hong-Kai
Chi, Zhi-Hong
He, Zhi-Song
Ye, Ding-Wei
Guo, Jun
Funding for this research was provided by:
Shanghai leaders’ foundation (81001131, 81370073)
The Project of the National Natural Science Foundation of China (81202004)